- Coromandel’s net income for the second quarter is 8.05 billion rupees, which is a 21% increase year-over-year and surpasses the estimated 7.18 billion rupees.
- Revenue for the quarter reached 96.5 billion rupees, marking a 30% rise from the previous year, and exceeded the forecast of 87.04 billion rupees.
- Total costs rose by 32% year-over-year to 87.1 billion rupees.
- Raw material costs increased by 40% to 47.2 billion rupees, coming in below the two estimates of 58.62 billion rupees.
- The company has agreed to a 1.6 billion rupee inter-corporate loan to its unit, NACL Industries.
- Coromandel’s shares fell by 3.9% to 2,166 rupees with a trading volume of 593,180 shares.
- Market sentiment includes 8 buy ratings, 2 hold ratings, and 2 sell ratings for Coromandel’s shares.
A look at Coromandel International Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts at Smartkarma have evaluated the long-term outlook for Coromandel International Ltd. based on their Smart Scores. The company has received a mixed assessment with a Value score of 2, Dividend score of 3, Growth score of 3, Resilience score of 4, and Momentum score of 3. This suggests that while Coromandel International may have solid resilience and moderate growth potential, its value proposition is not as strong.
Coromandel International Ltd. is a manufacturer of fertilizers and pesticides, producing both chemical and organic options as well as insecticides, fungicides, herbicides, and plant biostimulants. Looking ahead, investors may want to keep an eye on the company’s ability to maintain its business resilience and capitalize on any growth opportunities, despite its current valuation challenges.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
